Bevacizumab, a monoclonal antibody against VEGF, was recently tested in combination with radiotherapy and cisplatin chemotherapy in a phase II study [46] involving 49 evaluable, previously untreated patients with locally advanced cervical cancer. This evidence concerns the gene VEGFA and cervical cancer.